Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells
作者:Kyung-Hwa Jeon、Seojeong Park、Jae-Ho Shin、Ah-Reum Jung、Soo-Yeon Hwang、Seung Hee Seo、Hyunji Jo、Younghwa Na、Youngjoo Kwon
DOI:10.1016/j.ejmech.2022.114999
日期:2023.1
but not I and IIβ, was directly and proportionally associated with poor clinical outcome of Prostate cancer. Among a novel series of newly designed and synthesized 7-(3-aminopropyloxy)-substituted flavone analogues, compound 6, the most potent derivative, was further characterized and identified as a topo IIα catalytic inhibitor that intercalates into DNA and binds to the DNA minor groove with better
前列腺癌患者主要接受雄激素受体 (AR) 靶向药物作为主要治疗选择,因为前列腺癌与高度激活的 AR 信号相关。AR 扩增使前列腺癌细胞在 AR 靶向治疗下存活,从而导致去势抵抗。AR扩增在恩杂鲁胺耐药患者中更为常见。作为克服去势抵抗和提高恩杂鲁胺疗效的策略,用于去势抵抗性前列腺癌 (CRPC) 的第二代非甾体抗雄激素药物包括拓扑异构酶 II (topo II) 毒物,如依托泊苷和米托蒽醌,已与恩杂鲁胺。在本研究中,证实了 topo IIα 的扩增,但 I 和 IIβ 没有,与前列腺癌的不良临床结果直接且成比例地相关。在一系列新设计合成的 7-(3-氨基丙氧基)-取代黄酮类似物中,化合物6是最有效的衍生物,被进一步表征并鉴定为一种 topo IIα 催化抑制剂,可插入 DNA 并与 DNA 小沟结合,与依托泊苷(一种 topo II 毒物)相比具有更好的功效和更低的遗传毒性。化合物6在抑制 AR